CHIR99021

CHIR99021
Names
	IUPAC name 6-((2-((4-(2,4-Dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)amino)nicotinonitrile
Identifiers
CAS Number	252917-06-9 ;
3D model (JSmol)	Interactive image;
ECHA InfoCard	100.236.922
PubChem CID	9956119;
UNII	234CMT4GK4 ;
CompTox Dashboard (EPA)	DTXSID90179931 ;
	InChI InChI=1S/C22H18Cl2N8/c1-13-10-29-21(31-13)17-12-30-22(32-20(17)16-4-3-15(23)8-18(16)24)27-7-6-26-19-5-2-14(9-25)11-28-19/h2-5,8,10-12H,6-7H2,1H3,(H,26,28)(H,29,31)(H,27,30,32) Key: AQGNHMOJWBZFQQ-UHFFFAOYSA-N;
	SMILES N#CC1=CN=C(NCCNC2=NC=C(C3=NC(C)=CN3)C(C4=CC=C(Cl)C=C4Cl)=N2)C=C1;
Properties
Chemical formula	C25H18Cl2N8
Molar mass	501.38 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
	Infobox references

CHIR99021 is a chemical compound which acts as an inhibitor of the enzyme GSK-3.[1] It has proved useful for applications in molecular biology involving the transformation of one cell type to another.[2][3]

A mixture of CHIR99021 and valproic acid is claimed to increase the proliferation of inner ear stem cells [4]. This forms the basis of FX-322 in development by Frequency Therapeutics for the treatment of sensorineural hearing loss.

References

An, WF; Germain, AR; Bishop, JA; Nag, PP; Metkar, S; Ketterman, J; Walk, M; Weiwer, M; Liu, X; Patnaik, D; Zhang, YL; Gale, J; Zhao, W; Kaya, T; Barker, D; Wagner, FF; Holson, EB; Dandapani, S; Perez, J; Munoz, B; Palmer, M; Pan, JQ; Haggarty, SJ; Schreiber, SL (2010). "Discovery of Potent and Highly Selective Inhibitors of GSK3b". PMID 23658955. Cite journal requires |journal= (help)
Singh, VK; Kumar, N; Kalsan, M; Saini, A; Chandra, R (2015). "Mechanism of Induction: Induced Pluripotent Stem Cells (iPSCs)". Journal of Stem Cells. 10 (1): 43–62. PMID 26665937.
Takeda, Yukimasa; Harada, Yoshinori; Yoshikawa, Toshikazu; Dai, Ping (29 June 2018). "Chemical compound-based direct reprogramming for future clinical applications". Bioscience Reports. 38 (3). doi:10.1042/BSR20171650. PMC 5938430. PMID 29739872.
US Patent No. 10041047

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] An, WF; Germain, AR; Bishop, JA; Nag, PP; Metkar, S; Ketterman, J; Walk, M; Weiwer, M; Liu, X; Patnaik, D; Zhang, YL; Gale, J; Zhao, W; Kaya, T; Barker, D; Wagner, FF; Holson, EB; Dandapani, S; Perez, J; Munoz, B; Palmer, M; Pan, JQ; Haggarty, SJ; Schreiber, SL (2010). "Discovery of Potent and Highly Selective Inhibitors of GSK3b". PMID 23658955. Cite journal requires |journal= (help)

[2] Singh, VK; Kumar, N; Kalsan, M; Saini, A; Chandra, R (2015). "Mechanism of Induction: Induced Pluripotent Stem Cells (iPSCs)". Journal of Stem Cells. 10 (1): 43–62. PMID 26665937.

[3] Takeda, Yukimasa; Harada, Yoshinori; Yoshikawa, Toshikazu; Dai, Ping (29 June 2018). "Chemical compound-based direct reprogramming for future clinical applications". Bioscience Reports. 38 (3). doi:10.1042/BSR20171650. PMC 5938430. PMID 29739872.

[4] US Patent No. 10041047

CHIR99021

See also

References